Am J Transplant, Volume 21, Suppl 3 Archives - Page 9 of 139 - ATC Abstracts

2021 American Transplant Congress
Geographic Divergence in Waitlist Registration and Trends in Waitlist Removal for Liver Transplantation in Patients with Nonalcoholic Steatohepatitis (NASH)
C. Hanlon¹, B. Saberi², L. Yuan¹
¹Internal Medicine - Transplant Hepatology, University of Southern California, Los Angeles, CA, ²Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: This study aims to evaluate regional trends of waitlist (WL) registrations and removal for liver transplantation (LT) among United States (US) adults listed for…
2021 American Transplant Congress
Assessing the Impact of the New Liver Allocation Policy on Transplant Center and Organ Procurement Organization Logistics
W. P. Sawyer¹, A. Gracon²
¹General Surgery, Ochsner Health System, New Orleans, LA, ²Transplant Surgery, Ochsner Health System, New Orleans, LA
*Purpose: In February 2020, a new policy for liver allocation was instituted in an effort to reduce geographic disparity in median MELD at transplant. To…
2021 American Transplant Congress
Macrosteatosis in the US Pediatric Deceased Liver Donor Population, 2005-2018
J. Purvis, D. Dhall, C. McLeod, S. Sheikh, R. Cannon, K. Frey, J. Locke, B. Orandi
University of Alabama School of Medicine, Birmingham, AL
*Purpose: The pediatric obesity epidemic is associated with early signs of non-alcoholic fatty liver disease (NAFLD) such as increased hepatic macrosteatosis and liver enzymes. In…
2021 American Transplant Congress
Textbook Outcome: A Novel Metric in Lung Transplantation Outcomes
A. M. Ganapathi¹, B. A. Whitson¹, N. A. Mokadam¹, B. C. Keller², A. Logan¹, G. Brock¹, K. Washburn¹, A. D. Schenk¹
¹Surgery, Ohio State University Wexner Medical Center, Columbus, OH, ²Medicine, Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Lung transplant programs are typically assessed based on 1-/3-year survival, however other factors such as quality of life, freedom from rejection and oxygen, etc.,…
2021 American Transplant Congress
Pd-1 Inhibitor Treatment in Solid Organ Transplant Patients with Metastatic Cancer
C. Chung¹, H. Ko¹, H. Kim¹, K. Choi¹, A. Han¹, S. Min¹, H. Kang², J. Ha¹
¹Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ²Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: Solid organ transplant patients due to chronic immunosuppression have an increased risk of de novo cancer. Immune checkpoint inhibitors have been recently developed to…
2021 American Transplant Congress
Racial/ethnic and Sex Disparities in Renal Transplant Waitlisting Accounting for Pre-Waitlist Mortality
R. Hamoda¹, R. Patzer², M. Saunders¹
¹University of Chicago, Chicago, IL, ²Emory University, Atlanta, GA
*Purpose: The purpose of this study was to assess racial/ethnic and sex differences in access to the renal transplant deceased donor waiting list among incident…
2021 American Transplant Congress
Prostate Cancer Mortality is Not Worse Among Kidney Transplant Recipients Compared to Dialysis Patients
N. Sarabu¹, W. Dong², S. M. Koroukian²
¹University Hospital Cleveland Medical Center, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
*Purpose: Recent recommendations from expert panel of American Society of Transplantation (AST) state that most patients with prostate cancer (PCa) do not need to wait…
2021 American Transplant Congress
Offer Acceptance Models for Various Endpoints: Initial Response, Final Response, and Conversion from Provisional Yes to Yes
C. Martinez, M. Stuart, A. Placona
United Network for Organ Sharing, Richmond, VA
*Purpose: Offer acceptance models are routinely used for program evaluation and academic research, but the focus tends to be on modelling the final offer response.…
2021 American Transplant Congress
Impact of Insulin Therapy in Pancreas Transplantation Donors on Graft Outcomes: An Analysis of the Optn/unos Database
E. Montagud-Marrahi¹, F. Ausania², Y. Fundora², A. Amor³, E. Esmatjes³, J. Ferrer², I. Revuelta¹, D. Cucchiari¹, J. Rovira⁴, M. Musquera⁵, C. Fondevila², F. Diekmann¹, P. Ventura-Aguiar¹
¹Nephrology and Kidney Transplantation Department, Hospital Clinic de Barcelona, Barcelona, Spain, ²Hepatobiliopancreatic and Liver Transplant Department, Hospital Clinic de Barcelona, Barcelona, Spain, ³Endocrinology Department, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Laboratori Experimental de Nefrologia I Trasplantament (LENIT), CRB CELLEX, Fundació Clínic, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain, ⁵Urology Department, Hospital Clinic de Barcelona, Barcelona, Spain
*Purpose: Hyperglycemia requiring insulin treatment is frequent in critically ill patients and potential pancreas donors. Information on the impact of donor insulin use on pancreas…
2021 American Transplant Congress
Baseline Levels of Dd-cf Dna After Pancreas Transplantation: Using Dd-cfdna as an Indicator for Pancreas Rejection and Biopsy Avoidance
A. Yoo, I. Qian, A. Riedel, C. Cazac, A. Bartosic, J. S. Bromberg, J. Scalea
Department of Surgery, Division of Transplant, University of Maryland School of Medicine, Baltimore, MD
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) testing, which has been previously validated for monitoring kidney transplant (KTx) rejection, may provide an alternative to pancreas biopsy that…

« Previous Page
1
…
7
8
9
10
11
…
139
Next Page »